| Source: |
| Type: |
| VDAC1 is a pore-forming protein in the outer mitochondrial membrane that regulates metabolite flux (ATP/ADP, ions), mitochondrial–cytosolic communication, and apoptosis signaling. In Alzheimer’s disease, VDAC1 sits at a convergence point between mitochondrial dysfunction, oxidative stress, and neuronal death, all core features of AD pathophysiology. -Upregulated VDAC1 detected in AD post-mortem cortex and hippocampus. |
| 7982- | itraC, | Simultaneous Targeting of NPC1 and VDAC1 by Itraconazole Leads to Synergistic Inhibition of mTOR Signaling and Angiogenesis |
| - | in-vitro, | Nor, | HUVECs | - | in-vitro, | Lung, | A549 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | HEK293 |
| 7983- | itraC, | Antifungal drug itraconazole targets VDAC1 to modulate the AMPK/mTOR signaling axis in endothelial cells |
| - | in-vitro, | Nor, | HUVECs |
| 8089- | KAE, | Kaempferol impairs aerobic glycolysis against melanoma metastasis via inhibiting the mitochondrial binding of HK2 and VDAC1 |
| - | in-vitro, | Melanoma, | A375 | - | in-vitro, | Melanoma, | B16-F10 |
| 4862- | Uro, | Neuroprotective effect of Urolithin A via downregulating VDAC1-mediated autophagy in Alzheimer's disease |
| - | in-vivo, | AD, | NA | - | in-vitro, | Nor, | PC12 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:1 prod#:% Target#:1405 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid